• Folakemi T Odedina, Mark L Wieland, Kim Barbel-Johnson, and Jennifer M Crook.
• Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL. Electronic address: odedina.folakemi@mayo.edu.
• Mayo Clin. Proc. 2024 Jan 1; 99 (1): 159171159-171.

AbstractThe representation of racial and ethnic minority populations in clinical trials continues to be a challenge despite mandates, good intentions, and concerted efforts by funding agencies, regulatory bodies, and researchers to close the clinical trials gap. A lack of diversity in research results in both continued disparities and poorer health outcomes. It is thus imperative that investigators understand and effectively address the challenges of clinical trials participation by underrepresented populations. In this paper, we expound on best practices for participatory research by clearly defining the community, highlighting the importance of proper identification and engagement of strong community partners, and exploring patient- and provider-level barriers and facilitators that require consideration. A clearer understanding of the balance of power between researchers and community partners is needed for any approach that addresses clinical trials representation. Unintended biases in study design and methods may continue to prevent racial and ethnic minority participants from taking part, and significant organizational changes are necessary for efficient and transparent relationships. Comprehensive community engagement in research includes dissemination of clinical trial results within and in partnership with community partners. Through careful deliberation and honest reflection, investigators, institutions, and community partners can develop the tailored blueprints of research collaborations essential for true equity in clinical trials.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

6 keywords...

hide…